This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Generally speaking, doctors control large sums of money both professionally and personally, making them a highly desirable target audience for pharmaceutical companies, device and supply companies, SaaS, and even those outside the healthcare industry, like real estate brokers and investment advisors.
The key issue in the US isn’t the oversupply of physicians, test, procedures — it’s the cost of care, the cost of pharmaceuticals, the cost of all healthcare goods and services. How do we integrate lessons from the past and present? This is a significant inflection point for the healthcare system.
The key issue in the US isn’t the oversupply of physicians, test, procedures — it’s the cost of care, the cost of pharmaceuticals, the cost of all healthcare goods and services. How do we integrate lessons from the past and present? This is a significant inflection point for the healthcare system.
The key issue in the US isn’t the oversupply of physicians, test, procedures — it’s the cost of care, the cost of pharmaceuticals, the cost of all healthcare goods and services. How do we integrate lessons from the past and present? This is a significant inflection point for the healthcare system.
The key issue in the US isn’t the oversupply of physicians, test, procedures — it’s the cost of care, the cost of pharmaceuticals, the cost of all healthcare goods and services. How do we integrate lessons from the past and present? This is a significant inflection point for the healthcare system.
The key issue in the US isn’t the oversupply of physicians, test, procedures — it’s the cost of care, the cost of pharmaceuticals, the cost of all healthcare goods and services. How do we integrate lessons from the past and present? This is a significant inflection point for the healthcare system.
The key issue in the US isn’t the oversupply of physicians, test, procedures — it’s the cost of care, the cost of pharmaceuticals, the cost of all healthcare goods and services. How do we integrate lessons from the past and present? This is a significant inflection point for the healthcare system.
The key issue in the US isn’t the oversupply of physicians, test, procedures — it’s the cost of care, the cost of pharmaceuticals, the cost of all healthcare goods and services. How do we integrate lessons from the past and present? This is a significant inflection point for the healthcare system.
“Doing more procedures is not the answer to quality care — it is building a system and a culture that puts the resources of the entire team at play in the correct way.”. We can take the time to have the important conversations about patient goals, including those about end-of-life care that were so important during the pandemic.
HIPAA, GDPR regulations), data privacy risks (ie, that extend beyond the regulations), reputational risks (e.g., Federated learning allows pharmaceutical companies to access sought-after ‘multi-modal’ data from multiple hospitals in order to identify potential drug candidates and evaluate drug safety and efficacy.
The recent announcement of the prescription drug cost regulation blueprint, “American Patients First,” speaks to President Trump’s and Secretary Azar’s focus on regulatory reforms targeting the prices of medicine. Last year’s rate of growth was 4.6%.
We organize all of the trending information in your field so you don't have to. Join 19,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content